Pioglitazone Decreases Asymmetric Dimethylarginine Levels in Patients with Impaired Glucose Tolerance or Type 2 Diabetes
- 1 October 2013
- journal article
- research article
- Published by SAGE Publications in Rejuvenation Research
- Vol. 16 (5) , 344-351
Abstract
Background and Aims: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a biomarker and mediator of cardiovascular disease in patients with impaired glucose tolerance (IGT) or diabetes mellitus (DM). Advanced glycation end products (AGEs) and their receptor (RAGE) axis is involved in ADMA generation as well. However, it remains unclear whether pioglitazone could decrease ADMA levels by reducing RAGE expression in humans. Design and Methods: Forty-eight IGT or type 2 DM (T2DM) patients were assigned to receive either pioglitazone ( n =29) or glimepiride ( n =19) and evaluated at baseline and 16 weeks of follow-up. We compared the effects of pioglitazone and glimepride on ADMA and soluble form of RAGE (sRAGE) levels and then studied whether the changes in serum ADMA level (ΔADMA) after treatment with pioglitazone were correlated with ΔsRAGE. We further examined which Δclinical variables were independently associated with ΔADMA. Results: After 16-week treatments, fasting plasma glucose and glycated hemoglobin (HbA1c) values were comparably reduced in both groups. Compared with glimepiride, pioglitazone treatment significantly decreased ADMA levels and improved insulin sensitivity, while it elevated high-density lipoprotein cholesterol (HDL-C) and sRAGE values and increased body weight and waist circumference. In multiple stepwise regression analysis, log-transformed Δfibronectin were a sole independent determinant of log-transformed ΔADMA ( r =−0.551, R 2 =0.303). Conclusions: This study demonstrated that pioglitazone decreased serum ADMA levels in a glucose-lowering independent manner. Elevation of fibronectin by pioglitazone may contribute to the reduction of serum levels of ADMA in IGT or T2DM subjects, thus playing a protective role against cardiovascular disease.Keywords
This publication has 41 references indexed in Scilit:
- Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studiesDiabetic Medicine, 2013
- Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDFInternational Journal of Cardiology, 2012
- Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axisPharmacological Research, 2011
- Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activationBiochemical and Biophysical Research Communications, 2010
- Soluble form of a receptor for advanced glycation end products sRAGE as a biomarkerFrontiers in Bioscience-Elite, 2010
- Effect of Telmisartan on Nitric Oxide–Asymmetrical Dimethylarginine SystemHypertension, 2008
- Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney diseaseClinical and Experimental Nephrology, 2007
- Relation of Improvement in Endothelium-Dependent Flow-Mediated Vasodilation After Rosiglitazone to Changes in Asymmetric Dimethylarginine, Endothelin-1, and C-Reactive Protein in Nondiabetic Patients With the Metabolic SyndromeThe American Journal of Cardiology, 2006
- Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin‐induced diabetic rats and cultured endothelial cellsDiabetes/Metabolism Research and Reviews, 2006
- Pioglitazone Lowers Systemic Asymmetric Dimethylarginine by Inducing Dimethylarginine Dimethylaminohydrolase in RatsHypertension Research, 2005